BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
MLTX upcoming catalysts
MoonLake Immunotherapeutics AG: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 1 FDA event(s). Subscribe to MLTX (.ics).
Drugs: Sonelokimab, Risankizumab
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-01-04 est. | P3 | MoonLake Immunotherapeutics AG MLTX | NCT06641089 Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Arthritis, Psoriatic | active not recruiting | 600 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-11-01 (month) | PDUFA date (company-disclosed) | date passed | MoonLake Immunotherapeutics MLTX | PDUFA November 2026 - MoonLake Immunotherapeutics |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09-28 | P3 | MoonLake Immunotherapeutics AG MLTX | NCT06768671 An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurat | Hidradenitis Suppurativa | completed | 35 |
| 2026-05-28 | P3 | MoonLake Immunotherapeutics AG MLTX | NCT06641076 Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug | Arthritis, Psoriatic | active not recruiting | 960 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.